ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ibutamoren

Also written as “LUM-201” and “MK0677”.

Its studies are mostly in Dwarfism, Pituitary · Obesity · Hip Fractures · Alzheimer Disease, led by 2 companies.

Drug pageIbutamoren: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 21, 20259 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lumos Pharmaits history only75 open or runningphase 3since Apr 21, 2025Oct 26, 2020Dec 2027phase 3 · NCT06948214
Merck20 open or runningphase 2since Dec 15, 2003Dec 15, 2003none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2003First study: phase 2 study in Alzheimer DiseaseFirst studyNCT00074529 · 512 enrolled
  2. Aug 5, 2005Phase 2 study in Hip FracturesNCT00128115 · 83 enrolled · Germany, Norway, Spain and more

TargetBeta

GHSR →read by rule
“Ghrelin receptor agonist”ChEMBL 37, by rule

Studies

All 2 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00128115Hip Fractures · Germany, Norway, Spain and more2TerminatedAug 200783
NCT00074529Alzheimer Disease2CompletedJan 2006512

How it is read

Names in the registry

  • “LUM-201”, 7 entries
  • “MK0677”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.